Semapimod    (DrugBank: Semapimod)

1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease5

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00950105
(ClinicalTrials.gov)
July 200929/7/2009Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy SubjectsCrohn's DiseaseDrug: CPSI-2364 or placeboFerring PharmaceuticalsNULLCompleted18 Years55 YearsBoth30Phase 1United States
2NCT00741910
(ClinicalTrials.gov)
July 200322/8/2008Extension Study of Semapimod 60 mg IV x 3 DaysExtension Study of CNI-1493 for Treatment of Moderate to Severe Crohn's DiseaseCrohn's DiseaseDrug: SemapimodFerring PharmaceuticalsNULLCompleted18 YearsN/ABoth15Phase 2United States;Germany;Israel;Netherlands
3NCT00740103
(ClinicalTrials.gov)
December 200221/8/2008Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's DiseaseLong-term Study of Semapimod (CNI-1493) for Treatment of Moderate to Severe Crohn's Disease With Reference to Study CNI-1493-CD-04, 1 or 3 Days' Treatment vs. PlaceboCrohn's DiseaseDrug: SemapimodFerring PharmaceuticalsNULLCompleted18 YearsN/ABoth119Phase 2United States;Belgium;Germany;Israel;Netherlands
4NCT00739986
(ClinicalTrials.gov)
October 200220/8/2008Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus PlaceboA Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. PlaceboCrohn's DiseaseDrug: Semapimod;Drug: PlaceboFerring PharmaceuticalsNULLCompleted18 YearsN/ABoth152Phase 2United States;Belgium;Germany;Israel;Netherlands
5NCT00038766
(ClinicalTrials.gov)
June 20025/6/2002CNI-1493 for Treatment of Moderate to Severe Crohn's DiseaseA Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's DiseaseCrohn DiseaseDrug: semapimod;Drug: placeboFerring PharmaceuticalsNULLTerminated18 YearsN/ABoth33Phase 2United States